Your browser doesn't support javascript.
A proof of concept study for the differentiation of SARS-CoV-2, hCoV-NL63, and IAV-H1N1 in vitro cultures using ion mobility spectrometry.
Feuerherd, M; Sippel, A-K; Erber, J; Baumbach, J I; Schmid, R M; Protzer, U; Voit, F; Spinner, C D.
  • Feuerherd M; Institute of Virology, School of Medicine, Technical University of Munich, 81675, Munich, Germany. martin.feuerherd@tum.de.
  • Sippel AK; Institute of Virology, Helmholtz Zentrum München, Munich, Germany. martin.feuerherd@tum.de.
  • Erber J; B. Braun Melsungen AG, Branch Dortmund, Center of Competence Breath Analysis, BioMedicalCenter, Dortmund, Germany.
  • Baumbach JI; Department of Internal Medicine II, University Hospital Rechts Der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Schmid RM; B. Braun Melsungen AG, Branch Dortmund, Center of Competence Breath Analysis, BioMedicalCenter, Dortmund, Germany.
  • Protzer U; Department of Internal Medicine II, University Hospital Rechts Der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Voit F; Institute of Virology, School of Medicine, Technical University of Munich, 81675, Munich, Germany.
  • Spinner CD; Institute of Virology, Helmholtz Zentrum München, Munich, Germany.
Sci Rep ; 11(1): 20143, 2021 10 11.
Article in English | MEDLINE | ID: covidwho-1462040
ABSTRACT
Rapid, high-throughput diagnostic tests are essential to decelerate the spread of the novel coronavirus disease 2019 (COVID-19) pandemic. While RT-PCR tests performed in centralized laboratories remain the gold standard, rapid point-of-care antigen tests might provide faster results. However, they are associated with markedly reduced sensitivity. Bedside breath gas analysis of volatile organic compounds detected by ion mobility spectrometry (IMS) may enable a quick and sensitive point-of-care testing alternative. In this proof-of-concept study, we investigated whether gas analysis by IMS can discriminate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from other respiratory viruses in an experimental set-up. Repeated gas analyses of air samples collected from the headspace of virus-infected in vitro cultures were performed for 5 days. A three-step decision tree using the intensities of four spectrometry peaks correlating to unidentified volatile organic compounds allowed the correct classification of SARS-CoV-2, human coronavirus-NL63, and influenza A virus H1N1 without misassignment when the calculation was performed with data 3 days post infection. The forward selection assignment model allowed the identification of SARS-CoV-2 with high sensitivity and specificity, with only one of 231 measurements (0.43%) being misclassified. Thus, volatile organic compound analysis by IMS allows highly accurate differentiation of SARS-CoV-2 from other respiratory viruses in an experimental set-up, supporting further research and evaluation in clinical studies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antigens, Viral Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-99742-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antigens, Viral Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-99742-7